FIG 6.

IHVR-17028 treatment does not alter the cell surface expression of ACE2. FLP-IN/ACE2 cells were mock treated or treated with 50 μM IHVR-17028 in the absence or presence of 1 μg/ml tetracycline for 48 h. (A) Surface expression of ACE2 was examined by flow cytometry using an anti-myc antibody. (B) Binding of a SARS-CoV RBD-Ig fusion protein on the cell surface was assayed by flow cytometry. Mean fluorescence values and standard deviations from three independent experiments, obtained from cells treated under the conditions described above and stained with anti-myc antibody (C) or the SARS-CoV RBD-Ig fusion protein (D), are also presented.